CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
高危复发/难治性慢性淋巴细胞白血病及 Richter 综合征的细胞治疗
英文原题：Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome.
查看英文原题
Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管在慢性淋巴细胞白血病（CLL）中已经开发出高效的靶向B细胞增殖和抗凋亡通路的抑制剂，但这些治疗并非治愈性的，许多患者会对这些治疗产生不耐受或耐药。CLL向高级别淋巴瘤的转化——即所谓的里氏综合征（RS）——仍然是一种高度耐化学免疫治疗的疾病，而在CLL靶向抑制剂治疗后发生的转化尤为不利。鉴于此，异基因干细胞移植和CAR-T 细胞疗法等细胞治疗在这些疾病中仍在持续探索。我们综述了评估这些治疗方式在高危CLL和RS中应用的当前文献。我们还讨论了它们目前的局限性及其在治疗算法中的地位。
展开英文摘要原文
Despite the development of highly effective, targeted inhibitors of B-cell proliferation and anti-apoptotic pathways in chronic lymphocytic leukemia (CLL), these treatments are not curative, and many patients will develop either intolerance or resistance to these treatments.
Transformation of CLL to high-grade lymphoma-the so-called Richter syndrome (RS)-remains a highly chemoimmunotherapy-resistant disease, with the transformation occurring following targeted inhibitors for CLL treatment being particularly adverse. In light of this, cellular therapy in the form of allogenic stem cell transplantation and chimeric antigen receptor T-cell therapy continues to be explored in these entities.
We reviewed the current literature assessing these treatment modalities in both high-risk CLL and RS.
We also discussed their current limitations and place in treatment algorithms.
论文信息
- 作者
- Barbanti MC、Appleby N、Kesavan M、Eyre TA
- 单位
- Department of Clinical Haematology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.United Kingdom
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 35574335 · DOI 10.3389/fonc.2022.888109
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →